<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060991</url>
  </required_header>
  <id_info>
    <org_study_id>1801321-1</org_study_id>
    <nct_id>NCT05060991</nct_id>
  </id_info>
  <brief_title>Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients</brief_title>
  <acronym>ADIVKT</acronym>
  <official_title>Impact of Immunosuppression Adjustment on the Immune Response to SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients (ADIVKT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high&#xD;
      risk of COVID-19 associated complications and mortality. Retrospective studies so far have&#xD;
      shown that a majority of SOT recipients did not develop appreciable anti-spike antibody&#xD;
      response after a first, second, or even third dose of mRNA vaccine. Treatment with&#xD;
      antimetabolites was associated with poor vaccine response. The goal of this study is 1)&#xD;
      examine whether transient immunosuppression reduction improves the immune response to a third&#xD;
      dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients and 2) to assess the safety&#xD;
      of immunosuppression reduction before and after third dose SARS-CoV-2 mRNA vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized open-labeled study of kidney transplant recipients who have&#xD;
      previously received two doses of mRNA COVID-19 vaccine (either BNT162b2, Pfizer-BioNTech or&#xD;
      mRNA-1273, Moderna) and who are eligible to receive a 3rd dose of mRNA vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2021</start_date>
  <completion_date type="Anticipated">September 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized open-labeled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in anti-SARS-CoV-2 IgG titer to SARS-CoV-2 target proteins from baseline</measure>
    <time_frame>6 weeks after receipt of 3rd dose mRNA vaccine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who achieve high-positive antibody titer</measure>
    <time_frame>6 weeks after receipt of 3rd dose mRNA vaccine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>1 week to 16 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De Novo donor specific antibody (DSA) development</measure>
    <time_frame>4 week to 16 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in donor-derived cell free DNA from baseline</measure>
    <time_frame>1 week to 16 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glomerular filtration rate (GFR) from baseline</measure>
    <time_frame>1 week to 16 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proteinuria from baseline</measure>
    <time_frame>1 week to 16 weeks after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19</condition>
  <condition>Immunosuppression</condition>
  <condition>Vaccine Response Impaired</condition>
  <arm_group>
    <arm_group_label>Immunosuppression reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduction of immunosuppression before and after administration of a third dose of SARS-CoV-2 mRNA vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No change to immunosuppression before or after receipt of a third dose of SARS-Co-2 mRNA vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduction in antimetabolite immunosuppression</intervention_name>
    <description>Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination</description>
    <arm_group_label>Immunosuppression reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             study&#xD;
&#xD;
          -  First or repeat kidney transplant recipient&#xD;
&#xD;
          -  Negative or low positive antibody titer on SARS-CoV-2 antibody assay&#xD;
&#xD;
          -  On a mycophenolate or azathioprine based immunosuppressive regimen&#xD;
&#xD;
          -  &gt; 6 months post-transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Contraindication to SARS-CoV-2 vaccination (severe allergic reactions or anaphylaxis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanpreet Kaur</last_name>
      <phone>916-734-4009</phone>
      <email>axkaur@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Howes</last_name>
      <email>khowes@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aileen X Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Aileen X Wang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antimetabolites</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

